Reduced NAA-Levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Aboul Enein, Fahmy ^a   Krššák, Martin ^b   Höftberger, Romana ^c   Prayer, Daniela ^b   Kristoferitsch, Wolfgang ^a  

^a SMZ Ost Donauspital ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID; ASPARTIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; PARIETAL LOBE; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; WHITE MATTER; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

ADULT; ASPARTIC ACID; CHOLINE; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 77955343893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011625     Document Type: Article

References (38)

1. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359: 1221-1231.
2. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, et al. (2003) Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 62: 25-33.
3. Confavreux C, AlastairCompston (1996) The natural history of multiple sclerosis. In: AlastairCompston, ed. Mc Alpine's Multiple Sclerosis, 4th ed. PhiladelphiaPA: Churchill Livingstone Elsevier. pp 183-269.
4. Lassmann H, Brück W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17: 210-218.
5. Tintoré M, Rovira A, Martínez MJ, Rio J, Díaz-Villoslada P, et al. (2000) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 21: 702-706.
6. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 58: 840-846.
7. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, et al. (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14: 1157-1174.
8. Li DK, Held U, Petkau J, Daumer M, Barkhof F, et al. (2006) MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66: 1384-1389.
9. Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, et al. (2002) Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125: 2342-2352.
10. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, et al. (1999) In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 122: 1933-39.
11. De Stefano N, Filippi M, Miller D, Pouwels PJ, Rovira A, et al. (2007) Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 69: 1942-1952.
12. Sarchielli P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, et al. (1999) Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122: 513-521.
13. Sijens PE, Mostert JP, Oudkerk M, De Keyser J (2006) (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 16: 489-495.
14. Wattjes MP, Harzheim M, Lutterbey GG, Klotz L, Schild HH, et al. (2007) Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28: 1517-1522.
15. Kirov II, Patil V, Babb JS, Rusinek H, Herbert J, et al. (2009) MR Spectroscopy Indicates Diffuse Multiple Sclerosis Activity During Remission. J Neurol Neurosurg Psychiatry 80: 1330-1336.
16. Aboul-Enein F, Krssák M, Höftberger R, Prayer D, Kristoferitsch W (2010) Diffuse White Matter Damage Is Absent in Neuromyelitis Optica. AJNR Am J Neuroradiol AJNR Am J Neuroradiol 31: 76-79. Epub Sept. 2009.
17. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, et al. (2001) Javabased graphical user interface for the MRUI quantitation package. MAGMA 12: 141-152.
18. de Beer R, van den Boogaart A, van Ormondt D, Pijnappel WW, den Hollander JA, et al. (1992) Application of time-domain fitting in the quantification of in vivo 1H spectroscopic imaging data sets. NMR Biomed 5: 171-178.
19. Vanhamme L, van den Boogaart A, Van Huffel S (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129: 35-43.
20. Wansapura JP, Holland SK, Dunn RS, Ball WS, Jr. (1999) NMR relaxation times in the human brain at 3.0 tesla. J Magn Reson Imaging 9: 531-538.
21. Mlynárik V, Gruber S, Moser E (2001) Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed 14: 325-331.
22. Träber F, Block W, Lamerichs R, Gieseke J, Schild HH (2004) 1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging 19: 537-545.
23. Bagory M, Durand-Dubief F, Ibarrola D, Confavreux C, Sappey-Marinier D (2007) ''Absolute'' quantification in Magnetic Resonance Spectroscopy: validation of a clinical protocol in multiple sclerosis. Conf Proc IEEE Eng Med Biol Soc 1: 3458-3461.
24. Kreis R (1997) Quantitative localized 1H MR spectroscopy for clinical use. Prog Nucl Mag Res Sp 31: 155-195.
25. Ernst T, Kreis R, Ross BD (1993) Absolute quantification of water and metabolites in the human brain. I. Compartments and water. J Magn Reson B 102: 1-8.
26. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, et al. (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 20: 1619-1627.
27. Aboul-Enein F, Lassmann H (2005) Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? Acta Neuropathol 109: 49-55.
28. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, et al. (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121: 103-113.
29. van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, et al. (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46: 79-87.
30. Bellmann-Strobl J, Stiepani H, Wuerfel J, Bohner G, Paul F, et al. (2009) MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined crosssectional and longitudinal study. Eur Radiol 19: 2066-2074.
31. Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, et al. (2005) MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 53: 256-266.
32. Kolind SH, Mädler B, Fischer S, Li DK, MacKay AL (2009) Myelin water imaging: Implementation and development at 3.0T and comparison to 1.5T measurements. Magn Reson Med 62: 106-115.
33. Wattjes MP, Lutterbey GG, Harzheim M, Gieseke J, Träber F, et al. (2006) Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 16: 2067-2073.
34. Leary SM, Brex PA, MacManus DG, Parker GJ, Barker GJ, et al. (2000) A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Magn Reson Imaging 18: 455-459.
35. Jansen JF, Backes WH, Nicolay K, Kooi ME (2006) 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 240: 318-332.
36. Brief EE, Moll R, Li DK, Mackay AL (2009) Absolute metabolite concentrations calibrated using the total water signal in brain (1)H MRS. NMR Biomed 22: 349-354.
37. Helms G, Stawiarz L, Kivisäkk P, Link H (2000) Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions. Magn Reson Med 43: 102-110.
38. Bonneville F, Moriarty DM, Li BS, Babb JS, Grossman RI, et al. (2002) Wholebrain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 23: 371-375.